tbuckley/cabot-search huggingface dataset:
Aromatase inhibitors (AIs) with or without GnRH agonist as first-line hormone therapy in pre- and post-menopausal Korean women with metastatic breast cancer (MBC): Clinical outcomes in correlation with tumor ER/PR/HER2 status
Authors: J. Ro, K. S. Lee, B. H. Nam, H. S. Lim, Y. Kwon, S. Y. Kong, J. A. Seo, E. S. Lee
Journal: Journal of Clinical Oncology (2006)

10732 Background: Clinical outcomes of patients (pts) with MBC by AIs in comprehensive relationship with ER/PR/HER2 status have been scant that the study was performed to analyze their predictive values singly and in combination. Methods: 111 pts who took letrozole or anastrozole as first-line hormonal therapy for MBC were identified from the database at NCC Hospital between Nov. 2001 and Aug. 2005. Pts on AIs concomitantly with or immediately followed by chemotherapy were excluded. AIs/GnRH agonists were used when hormonal levels were not postmenopausal. ER/PR were scored strong, intermediate or weak. HER2+ was IHC 3+ or FISH+. HER2− was IHC 0, 1+ or 2+/FISH−. Clinical benefit (CB) included CR/PR/improving or SD ≥6 months. Results: Median age was 54 years (range, 29–78). Overall 66% achieved CB (CR/PR 18%, improving 26%, and SD ≥ 6mo 22%) with median TTP, 9 mo (range, 1–50, 95% CI, 7–11), and median survival, 41 mo (range, 2–50). Age, AIs with (20) vs. without (91) GnRH agonist, DFI ≤ vs. &gt; 24 mo, adjuvant tamoxifen, or prior metastatic chemotherapy did not affect clinical outcomes. Disease sites (%) were bone (64), LN (52), lung/pleura (41), liver (25), breast (20) and skin (7). Bone only disease had longer TTP (p = 0.004), while liver involvement was associated with short TTP (p = 0.0001)/OS (p = 0.007). ER was 56% strong +, 21% intermediate +, 15% weak +, 5% - and 3% unknown, PR: 24% strong +, 23% intermediate +, 24% weak +, 23% -, and 5% unknown, and HER2: 23% +, 67% -, and 10% unknown. Staining intensity did not affect CB in ER + tumors. More CB (p = 0.002)/longer TTP (p = 0.003) with strong/intermediate PR + tumors vs. weak PR + /PR − tumors, and more CB with ER + /PR + tumors vs. ER + /PR − tumors (P = 0.016) were observed. More CB with HER2 − tumors vs. HER2 + tumors (p = 0.001), and with PR + /HER2 − tumors vs. the rest (PR − /HER − , PR + /HER + , PR − /HER + ) (p = 0.0007) were seen. HER2 positivity was associated with less CB (p = 0.0004)/shorter TTP (p = 0.0157) in ER + /PR + tumors vs. no influence on CB (p = 0.245)/TTP (p = 0.52) in ER + /PR − tumors. Conclusions: AIs with or without GnRH agonist are effective therapy for pts with MBC, specifically with ER + /PR + /HER2 − tumors regardless of ages. No significant financial relationships to disclose.
Effect of social or health insurance status on outcome of patients with early breast cancer
Authors: J. K. Jueckstock, C. Scholz, A. Brandelik, B. K. Rack, H. L. Sommer, W. J. Janni, K. Friese
Journal: Journal of Clinical Oncology (2009)

6609 Background: Recent studies in the US showed a relationship between state of social or health insurance of cancer patients and their overall survival (OAS). ([1] Banerjee M et al, Cancer. 2007;110:2169–2177. [2] Griggs JJ et al, J Clin Oncol. 2007;25:2522–2527. [3] Brookfield KF et al, Cancer. 2008.) In Germany 91% of all women have a compulsory health insurance whereas 9% have private health coverage. There are no pts without health insurance in Germany. Methods: In a retrospective analysis of 1846 German early breast cancer pts correlation between state of social and health insurance and OAS was investigated. 59.6% of the pts had a social insurance whereas 40.4% had none. 69.1% of the pts carried compulsory health insurance while 30.9% had private coverage. Among the pts with compulsory health insurance 56.6% had had a professional education and 41.5% were working whereas among the pts with private coverage 66.2% were professionally experienced and 43.9% were working. Age, tumor size, lymph node metastases, and tumor grading were well balanced between the two groups. 25.4% of all pts had undergone mastectomy and 72.6% had had a breast conserving therapy. In 2.0% of the pts no breast surgery was performed. 33.6% of all pts received adjuvant chemotherapy while endocrine therapy or radiotherapy was administered to 40.1% and 61.1% respectively. Results: OAS as expected was strongly correlated to established prognostic factors like age, tumor size, lymph node status, and grading (p &lt; 0.001 respectively). However, OAS of the pts did not correlate to either social (p = 0.110) or health (p = 0.659) insurance state. Neither mattered the professional education of the pts concerning OAS (p = 0.217). Conclusions: Unlike the American results there was no correlation seen between state of social or health insurance for German early breast cancer pts. Thus, although pts with private coverage are supposed to receive more intensive medical care outcome for these pts concerning OAS does not exceed that of pts with compulsory insurance. No significant financial relationships to disclose.
One Effect Size Does Not Fit All—Is the Depression-Inflammation Link Missing in Racial/Ethnic Minority Individuals?
Authors: Jesse C. Stewart
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 10654: Absolute Hyperemic Myocardial Blood Flow is Impaired in Non-Ischemic Dilated Cardiomyopathy and is Related to the Severity of Left Ventricular Systolic Dysfunction
Authors: Ankur Gulati, Kaushiga Krishnathasan, Li-Yueh Hsu, Aamir Ali, Tevfik Ismail, Pedro Ferreira, Nizar Ismail, Carla Goncalves, Natasha Davendralingam, Rick Wage, Michael Roughton, Peter Gatehouse, Andrew Jabbour, Dudley J Pennell, Andrew E Arai, Sanjay Prasad
Journal: Circulation (2012)

Introduction: Myocardial perfusion reserve (MPR) is reduced in non-ischemic DCM. Microvascular ischemia may therefore be important in this condition. Since MPR is a ratio, absolute hyperemic myocar...
PRISMA harms checklist: improving harms reporting in systematic reviews
Authors: Liliane Zorzela, Yoon K Loke, John P Ioannidis, Su Golder, Pasqualina Santaguida, Douglas G Altman, David Moher, Sunita Vohra
Journal: BMJ (2016)

<b>Introduction</b>&nbsp;For any health intervention, accurate knowledge of both benefits and harms is needed. Systematic reviews often compound poor reporting of harms in primary studies by failing to report harms or doing so inadequately. While the PRISMA statement (Preferred Reporting Items for Systematic reviews and Meta-Analyses) helps systematic review authors ensure complete and transparent reporting, it is focused mainly on efficacy. Thus, a PRISMA harms checklist has been developed to improve harms reporting in systematic reviews, promoting a more balanced assessment of benefits and harms. <b>Methods</b>&nbsp;A development strategy, endorsed by the EQUATOR Network and existing reporting guidelines (including the PRISMA statement, PRISMA for abstracts, and PRISMA for protocols), was used. After the development of a draft checklist of items, a modified Delphi process was initiated. The Delphi consisted of three rounds of electronic feedback followed by an in-person meeting. <b>Results</b>&nbsp;The PRISMA harms checklist contains four essential reporting elements to be added to the original PRISMA statement to improve harms reporting in reviews. These are reported in the title ("Specifically mention 'harms' or other related terms, or the harm of interest in the review"), synthesis of results ("Specify how zero events were handled, if relevant"), study characteristics ("Define each harm addressed, how it was ascertained (eg, patient report, active search), and over what time period"), and synthesis of results ("Describe any assessment of possible causality"). Additional guidance regarding existing PRISMA items was developed to demonstrate relevance when synthesising information about harms. <b>Conclusion</b>&nbsp;The PRISMA harms checklist identifies a minimal set of items to be reported when reviewing adverse events. This guideline extension is intended to improve harms reporting in systematic reviews, whether harms are a primary or secondary outcome.
Altered calcium-homeostasis of cisplatin-resistant non small cell (NSLC) and small cell lung (SCLC) cancer cells
Authors: A. Bergner, K. Schroedl, H. Oelmez, R. M. Huber
Journal: Journal of Clinical Oncology (2008)

22185 Background: Chemotherapy in advanced lung cancer often leads to encouraging responses, but, in the course of the treatment, resistance to chemotherapy ultimately limits the life expectancy of the patient. The mechanisms of resistance to cisplatin, which is one of the most effective and most frequently used chemotherapeutics in lung cancer, are still not understood. We aimed at investigating if the intracellular Ca2+-homeostasis may be related to cisplatin resistance. Methods: The squamous cell lung carcinoma cell line EPLC and the small cell lung cancer cell line H1339 were exposed to cisplatin analogue to the in vivo pharmacokinetics. Changes in the cytoplasmic Ca2+-concentration ([Ca2+]c) were recorded using fluorescence microscopy and protein expression was quantified using Western Blot analysis and immuno-fluorescence. Results: Four "cycles" of cisplatin led to partial resistance in EPLC and H1339 cells. The partial resistance could be mimicked by buffering [Ca2+]c using BAPTA. In the resistant clones of both cell types, the Ca2+-content of the endoplasmic reticulum (ER) was decreased. In EPLC cells, this was correlated with an increased expression of the inositol-1,4,5-trisphosphate receptor (IP3R). In H1339 cells, the decrease Ca2+-content of the ER was correlated with a decreased expression of sarco/endoplasmic reticulum Ca2+-ATPases (SERCA). Using the siRNA technique, we could show that the modified expression of the respective proteins in fact altered the cisplatin sensitivity. Conclusions: We conclude that a decreased Ca2+- content of the ER contributes to cisplatin resistance and show for the first time that upregulation of the IP3R and decreased expression of SERCA are involved in cisplatin-resistance. No significant financial relationships to disclose.
Preliminary phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
Authors: S. Beslija, M. Banjin, S. Jungic, N. Obralic, G. Kecman-Malcic, I. Rakita, B. Salkic, A. Pasic, L. Tinjic, E. Ajanovic
Journal: Journal of Clinical Oncology (2007)

14502 Background: The oral fluoropyrimidine X (Xeloda®) has improved efficacy, safety and convenience compared with 5-FU/LV in MCRC [Van Cutsem et al. Br J Cancer 2004] and early-stage colon cancer [Twelves et al. NEJM 2005]. A recent study showed that I + X q2w is active and well tolerated [Garcia-Alfonso et al. ESMO 2006]. The humanized monoclonal antibody A (Avastin®) targets VEGF and limits tumor angiogenesis. The addition of A to 5-FU/LV/I (IFL regimen) results in significant improvements in survival among pts with MCRC [Hurwitz et al. NEJM 2004]. Replacing 5-FU/LV with X in this combination is a logical step forward. Here we report data from an open-label phase II trial of XIA in MCRC. Methods: Pts with untreated, histologically confirmed MCRC received I 175 mg/m 2 i.v. d1, X 1000 mg/m 2 orally bid d2–8, and A 5 mg/m 2 d1. Treatment was repeated q2w x12 cycles in the absence of disease progression or unacceptable toxicity. Pts without progressive disease after 12 cycles of XIA continued on the same dose of A + X 1500 mg/m 2 bid d2–8, q2w. The primary endpoint was progression-free survival (PFS); secondary endpoints were response rate (RECIST), overall survival (OS), safety, and quality of life. Results: 24 out of a planned total of 32 pts have been enrolled. Baseline characteristics are: M/F 50%/50%; median age 53 years (range 30–70); disease stage at initial diagnosis IIIA/IIIB/IV 29%/21%/50%; no. of metastatic sites 1/&gt;1 50%/50%; most common metastatic site liver; prior adjuvant therapy 33% (Mayo 5-FU/LV). Pts received a median of 12 cycles (range 1–18) of XIA. All 24 pts are evaluable for safety and 22 for efficacy. The overall response rate is 77% (4 CR, 13 PR); 2 pts (9%) have stable disease and 3 have progressed. One pt has died. Median PFS and median OS have not yet been reached. The only grade 3 adverse events are diarrhea (13%), fatigue (4%), mucositis (4%), enteritis (4%), ileus (4%); there is one report of grade 4 leucopenia. All other adverse events are mild-to-moderate. Conclusions: The XIA combination appears to be highly active and well tolerated as first-line treatment for MCRC, providing support for further evaluation of this combination. No significant financial relationships to disclose.
Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study.
Authors: D. A. Richards, D. M. Kocs, A. I. Spira, A. D. McCollum, K. A. Boehm, F. Zhan, L. Asmar
Journal: Journal of Clinical Oncology (2011)

4015 Background: Advanced adenocarcinoma of the gastroesophageal junction and/or stomach is standardly treated by combination chemotherapy with minimal improvements in survival. This study evaluated the value of adding cetuximab (C) to combination chemotherapy in this disease. Methods: The primary objective of this noncomparative study was progression-free survival (PFS); secondary objectives were 1-yr survival, response rate, time to response (TTR), duration of response (DOR), and safety. Treatment (Tx): Arm 1: DOCOX = docetaxel 60 mg/m2 plus oxaliplatin 130 mg/m2 on Day 1 of each 21-day cycle. Arm 2: DOCOX + C = DOCOX with C 400 mg/2 1st dose, then 250 mg/m2weekly. Key inclusion: stage IV adenocarcinoma of the GEJ/stomach; measurable disease; ECOG 0-2; and normal renal, hepatic, and marrow function; exclusion: any prior Tx other than adjuvant radiation with 5-FU/leucovorin. Results: 150 pts enrolled; 75/arm. Demographics Arm 1/2: male 79%/80%, median age 61/64 yrs; disease site: gastric 44%/41%, GEJ 51%/55%, both 5%/4%; 93%/96% had surgery, 7%/5% had radiation. Response rates/arm: 24%/29%. Median PFS was 4.7/5.1 mos (ranges, <1-24.8/<1-10.4); 1-yr survival was 40%/32%, median overall survival was 9.0/8.5 months; median TTR was 1.3/1.3 mos, and median DOR was 13.8/7.2 mos. The most frequent grade 3-4 treatment-related adverse events (AEs) included: neutropenia (44%/40%) diarrhea and febrile neutropenia (12%/17%, each), and fatigue (10%/15%). Analysis of KRAS is ongoing. Conclusions: The addition of C to DOCOX may improve RR minimally; there appears to be no significant improvement in PFS, OS, or 1-year survival. C did not produce clinically significant benefit when added to the backbone of DOCOX. Toxicities were consistent with the known safety profiles of the study drugs. Supported in part by grants from sanofi-aventis, Bridgewater, NJ and Lilly/ImClone, Indianapolis, IN.
Brief Communication: Frequency of Mammary Cell Division in Relation to Age: Its Significance in the Induction of Mammary Tumors by Carcinogen in Rats2
Authors: Hiroshi Nagasawa, Reiko Yanai
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Brief Communication: Frequency of Mammary Cell Division in Relation to Age: Its Significance in the Induction of Mammary Tumors by Carcinogen in Rats Get access Hiroshi Nagasawa, Hiroshi Nagasawa Search for other works by this author on: Oxford Academic PubMed Google Scholar Reiko Yanai Reiko Yanai Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 2, February 1974, Pages 609–610, https://doi.org/10.1093/jnci/52.2.609 Published: 01 February 1974 Article history Received: 27 September 1973 Accepted: 11 October 1973 Published: 01 February 1974
Influence of nebulized drugs on ciliary activity in vitro
Authors: Mieke Boon, Mark Jorissen, Marijke Proesmans, Martine Jaspers, Kris De Boeck
Journal: European Respiratory Journal (2013)

Introduction: The efficacy of several inhaled drugs is well proven in the treatment of cystic fibrosis (CF). Their use is however extrapolated to other chronic diseases, without clear evidence of benefit. In addition, the influence of inhaled drugs on ciliary activity has not been studied.  Objective: To examine the influence of inhaled drugs on ciliary beat frequency (CBF) in an  in vitro  nebulization model. Isotonic saline (IS), hypertonic saline (HS) and salbutamol (S) were used as neutral, inhibitory and stimulatory control to validate the model. Tobi® (T), Obracin® (O), colistimethate (C) and dornase alpha (D) were the test drugs.  Methods: Non CF nasal epithelial cells were cultured as monolayer. On day 4 to 6, confluent cell monolayers were exposed to nebulization in an aerosol chamber for 10 minutes. Images were acquired with a high-speed camera, and CBF was expressed as % of the starting value. CBF until 60 minutes after nebulization was compared between the test condition and IS using mixed model statistics. Per drug, 3 samples of 3 different patients were evaluated on 3 consecutive days.  Results: IS did not result in change in CBF. HS resulted in a decrease of CBF to 77% (p 0.021 versus IS), with complete spontaneous recovery at 60 min post nebulization. S resulted in an increase of CBF to 116% (p 0.05). T did not alter CBF (p 0.566), although O caused a decrease of CBF to 59.4% (p 0.0001). C and D respectively caused a small decrease of CBF to 90.7% (NS p 0.085) and increase to 108.5% (p 0.001).  Conclusion: Inhaled drugs can influence CBF, due to the product itself, the pH and osmolarity of the solution or to solvents in the solution. This may be relevant to their  in vivo  efficacy or tolerability.
Androgen deprivation therapy (ADT) and cardiovascular (CV) risk: Analysis of German Statutory Health Insurance (SHI) data.
Authors: Christoph Ruessel, Susanne Guthoff-Hagen, Verena Donatz
Journal: Journal of Clinical Oncology (2015)

219 Background: ADT is an established part of the guideline-oriented therapy of prostate cancer (PCa). Concerns regarding increased CV risks associated with ADT were raised by the FDA in 2010. Results from a pooled data-analysis of six prospective randomised trials suggest a lower number of CVevents in patients treated with the GnRH antagonist Degarelix compared with GnRH agonist treated patients with preexisting cardiovascular disease [Albertsen P. et al: Eur Urol 2014; 65: 565-73]. Objective: Can SHI data confirm the observation that the risk for CVevents varies depending on the substance used for ADT. Methods: Retrospective data sets of 4 Mio assured people from SHI funds from the years 2009-2012 were analysed to identify PCa patients treated with ADT, GnRH agonists and GnRH antagonists, respectively. An age-adjusted reference group with 1.1 Mio non-PCa persons was identified in the data sets. Results: 44.166 patients suffering from PCa were identified. Of those 10.611 patients were treated with ADT. 10.554 with GnRH agonists and 132 with GnRH antagonists, respectively. An increased prevalence for relevant baseline CV diseases was observed in ADT treated patients compared to the Non-PCa reference group (diabetes mellitus: 28.66% vs 17.43%.; CAD: 35.77% vs 15.70%; Heart failure: 27.54% vs 9.64%). The rate of heart attack and stroke (CVevents) after treatment begin with ADT was determined: 2.37% in the reference group, 5.9% in the PCa group, 7.8% in the ADT group, 2.3% in the GnRH antagonist group. All CVevents in GnRH antagonist group occurred in high risk patients, only. The urologist examined and reported the state of CV risk for 25% of the PCa patients, only. Urologists examine and treat statistically significantly more patients with a combination of PCa and CVevents than general practitioners (30 vs. 5 per year/per physician). Conclusions: This retrospective analysis confirms the hypothesis that the risk of CVevents varies by using different ADT. The risk might be lower by using GnRH antagonists. A close collaboration of urologists, general practitioners and cardiologists is therefore recommended in the management of PCa patients.
Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study
Authors: Torunn I Yock, Beow Y Yeap, David H Ebb, Elizabeth Weyman, Bree R Eaton, Nicole A Sherry, Robin M Jones, Shannon M MacDonald, Margaret B Pulsifer, Beverly Lavally, Annah N Abrams, Mary S Huang, Karen J Marcus, Nancy J Tarbell
Journal: The Lancet Oncology (2016)
Identification of Patients Who May Benefit From Prophylactic Immunotherapy After Bone Marrow Transplantation for Acute Myeloid Leukemia on the Basis of Lymphocyte Recovery Early After Transplantation
Authors: Ray Powles, Seema Singhal, Jennifer Treleaven, Samar Kulkarni, Clive Horton, Jayesh Mehta
Journal: Blood (1998)